drugset / Trial / NCT04844983
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this trial is to evaluate safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with cutaneous squamous cell carcinoma (in situ) skin cancer (isSCC).
Timeline
- Start
- 2021-05-18
- Primary completion
- 2022-08-24
- Completion
- 2022-12-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STP705 | Small interfering RNA (siRNA) | 30 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 60 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 90 ug | Other |